A:NYE-Agilent Technologies Inc (USD)

COMMON STOCK | Diagnostics & Research | NYE

Last Closing Price

USD 120.79

Change

-2.29 (-1.86)%

Market Cap

USD 36.25B

Volume

1.34M

Avg Analyst Target

USD 163.00 (+34.94%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Agilent Technologies Inc (A) Stock Analysis:
Based on the Agilent Technologies Inc stock forecasts from 9 analysts, the average analyst target price for Agilent Technologies Inc is USD 163.00 over the next 12 months. Agilent Technologies Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Agilent Technologies Inc is Slightly Bullish , which is based on 10 positive signals and 5 negative signals. At the last closing, Agilent Technologies Inc’s stock price was USD 120.79. Agilent Technologies Inc’s stock price has changed by +5.97% over the past week, -2.46% over the past month and -6.18% over the last year.

About

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-18 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
TMO Thermo Fisher Scientific Inc

-12.43 (-2.24%)

USD217.10B 28.91 20.20
DHR Danaher Corporation

-5.37 (-2.16%)

USD181.02B 28.82 19.89
DHR-PA Danaher Corporation

N/A

USD169.33B 213.72 N/A
IQV IQVIA Holdings Inc

-9.43 (-4.56%)

USD39.08B 37.29 17.49
MTD Mettler-Toledo International I..

-41.86 (-3.39%)

USD28.04B 37.72 26.66
LH Laboratory Corporation of Amer..

-5.30 (-2.14%)

USD22.97B 11.37 7.55
WAT Waters Corporation

-1.67 (-0.50%)

USD19.99B 29.71 20.42
PKI PerkinElmer Inc

-5.14 (-3.48%)

USD18.62B 18.27 14.47
DGX Quest Diagnostics Incorporated

-1.32 (-0.94%)

USD16.49B 9.32 6.64
CRL Charles River Laboratories Int..

-11.19 (-4.74%)

USD12.00B 31.08 17.15

ETFs Containing A

Symbol Name Weight Mer Price(Change) Market Cap
IWP iShares Russell Mid-Cap G.. 0.00 % 0.23 %

-3.85 (-4.57%)

USD12.01B
HIG:CA Brompton Global Healthcar.. 0.00 % 0.97 %

N/A

USD0.05B
GNOM Global X Genomics & Biote.. 0.00 % 0.50 %

-0.48 (-3.99%)

USD0.13B
XRSM:XETRA Xtrackers (IE) Public Lim.. 0.00 % 0.02 %

-0.57 (-1.80%)

USD0.11B
ZGEN:CA BMO MSCI Genomic Innovati.. 0.00 % 0.40 %

-0.34 (-1.72%)

N/A
MJJ MicroSectors Cannabis ETN.. 0.00 % 0.70 %

N/A

N/A
MJO MicroSectors Cannabis 2X .. 0.00 % 0.95 %

N/A

N/A
EDOC Global X Telemedicine & D.. 0.00 % 0.68 %

-0.41 (-3.46%)

N/A
DDOC:XETRA Global X Telemedicine & D.. 0.00 % 0.68 %

-0.14 (-1.62%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.34% 56% F 25% F
Dividend Return 0.26% 67% D+ 15% F
Total Return -24.08% 56% F 24% F
Trailing 12 Months  
Capital Gain -7.23% 56% F 59% F
Dividend Return 0.62% 67% D+ 10% F
Total Return -6.61% 56% F 54% F
Trailing 5 Years  
Capital Gain 115.20% 69% D+ 90% A-
Dividend Return 6.11% 80% B- 19% F
Total Return 121.31% 69% D+ 89% B+
Average Annual (5 Year Horizon)  
Capital Gain 24.43% 56% F 85% B
Dividend Return 0.88% 86% B 20% F
Total Return 25.30% 63% D 84% B
Risk Return Profile  
Volatility (Standard Deviation) 24.06% 56% F 47% F
Risk Adjusted Return 105.17% 81% B- 95% A
Market Capitalization 36.25B 80% B- 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 30.65 43% F 20% F
Price/Book Ratio 6.64 20% F 10% F
Price / Cash Flow Ratio 24.41 27% F 14% F
EV/EBITDA 20.14 42% F 19% F
Management Effectiveness  
Return on Equity 24.20% 81% B- 81% B-
Return on Invested Capital 15.60% 75% C 81% B-
Return on Assets 9.12% 75% C 88% B+
Debt to Equity Ratio 50.64% 67% D+ 60% D-
Technical Ratios  
Dividend Yield 0.68% 57% F 9% F
Short Ratio 2.43 60% D- 45% F
Short Percent 1.77% 67% D+ 67% D+
Beta 1.05 50% F 48% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector